{
    "clinical_study": {
        "@rank": "25111", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "One intratympanic injection of latanoprost (Day1)"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One intratympanic injection of placebo"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Three intratympanic injections of latanoprost (Day 1, 2 and 3)"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Three intratympanic injections of placebo (Day 1, 2 and 3)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the dose regimen, efficacy and safety  of\n      latanoprost for the treatment of Meni\u00e8re's disease."
        }, 
        "brief_title": "Latanoprost for the Treatment of Meni\u00e8re's Disease", 
        "condition": "Meni\u00e8re's Disease", 
        "condition_browse": {
            "mesh_term": "Meniere Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Definitive unilateral Meni\u00e8re's disease (AAO-HNS 1995)\n\n          -  Disease stage II - IV: PTA4 (Pure Tone Average) (0.5, 1.0, 2.0 and 3.0kHz) between\n             25dB and 65dB\n\n          -  Speech discrimination score in silence: No better than 85%\n\n          -  At least three vertigo attacks (lasting \u2265 20 minutes) during the last three months\n             prior to inclusion\n\n          -  Tinnitus during the last three months prior to inclusion\n\n          -  Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Medical or psychiatric conditions which could jeopardize or would compromise the\n             subject's ability to participate in the trial or decrease the likelihood of obtaining\n             satisfactory data to achieve the objective of the trial, dementia, alcohol or\n             substance abuse.\n\n          -  Bilateral Meni\u00e8re's disease\n\n          -  Chronic otitis media on the ear affected by Meni\u00e8re's disease\n\n          -  Subjects not fluent in Swedish language\n\n          -  Bronchial asthma\n\n          -  Previous intratympanic injection of gentamicin or surgical therapy\n\n          -  Previous intratympanic steroid therapy less than six months prior to inclusion\n\n          -  Known hypersensitivity to local anesthetics\n\n          -  Pregnant women\n\n          -  Nursing mothers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973114", 
            "org_study_id": "M 05 -  2013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 3"
                ], 
                "intervention_name": "Latanoprost", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 2", 
                    "Group 4"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Latanoprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Meni\u00e8re's disease", 
            "Vertigo", 
            "Hearing loss", 
            "Tinnitus"
        ], 
        "lastchanged_date": "November 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Falun", 
                        "country": "Sweden"
                    }, 
                    "name": "Falu Lasarett"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6teborg", 
                        "country": "Sweden"
                    }, 
                    "name": "Sahlgrenska Universitetssjukhuset"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karlstad", 
                        "country": "Sweden"
                    }, 
                    "name": "Centralsjukhuset i Karlstad"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kristianstad", 
                        "country": "Sweden"
                    }, 
                    "name": "Centralsjukhuset i Kristianstad"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lule\u00e5", 
                        "country": "Sweden"
                    }, 
                    "name": "Sunderby Sjukhus"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "Lund University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Karolinska Universitetssjukhuset"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "V\u00e4ster\u00e5s", 
                        "country": "Sweden"
                    }, 
                    "name": "V\u00e4stmanlands Sjukhus i V\u00e4ster\u00e5s"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00d6rebro", 
                        "country": "Sweden"
                    }, 
                    "name": "University Hospital \u00d6rebro"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Meni\u00e8re's Disease", 
        "overall_contact": {
            "email": "fredrik.henell@synphora.com", 
            "last_name": "Fredrik Henell, Dr Med Sci", 
            "phone": "+ 46 70 325 38 47"
        }, 
        "overall_official": {
            "affiliation": "Lund University Hospital", 
            "last_name": "Mikael Karlberg, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in speech discrimination score in noise from Baseline", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in speech discrimination score in noise from Baseline", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Change in pure tone audiometry from Baseline", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Change in THI-25 (Tinnitus Handicap Inventory) score from Baseline", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Change in hearing (Likert scale), tinnitus (Likert scale) and vertigo (Likert scale) from run-in period", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Change in proportion of days with vertigo attacks from run-in period", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Comparison of number of drop attacks in each treatment arm", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Evaluation of adverse events and vital signs as measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Synphora AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Synphora AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}